Finding a treatment for critically ill COVID-19 patients: alpha-1 antitryspin clinical trial
A clinical trial conducted by researchers from RCSI University of Medicine and Health Sciences and Beaumont Hospital Dublin has indicated an effective treatment for critically ill COVID-19 patients. The study, published today in Med, investigates the effects of using an anti-inflammatory protein, alpha-1 antitryspin (AAT), to treat COVID-19 patients who have progressed to acute respiratory distress